Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avis › Tidsskriftartikel › Forskning › peer review
Protein Analysis of the TGFBIR124H Mouse Model Gives Insight into Phenotype Development of Granular Corneal Dystrophy. / Lukassen, Marie V.; Poulsen, Ebbe T.; Donaghy, Jack; Mogensen, Emilie H.; Christie, Kathleen A.; Roshanravan, Hila; DeDioniso, Larry; Nesbit, M. Andrew; Moore, Tara; Enghild, Jan J.
I: Proteomics - Clinical Applications, Bind 14, Nr. 6, 1900072, 11.2020.Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avis › Tidsskriftartikel › Forskning › peer review
}
TY - JOUR
T1 - Protein Analysis of the TGFBIR124H Mouse Model Gives Insight into Phenotype Development of Granular Corneal Dystrophy
AU - Lukassen, Marie V.
AU - Poulsen, Ebbe T.
AU - Donaghy, Jack
AU - Mogensen, Emilie H.
AU - Christie, Kathleen A.
AU - Roshanravan, Hila
AU - DeDioniso, Larry
AU - Nesbit, M. Andrew
AU - Moore, Tara
AU - Enghild, Jan J.
PY - 2020/11
Y1 - 2020/11
N2 - Purpose: Mutations in the transforming growth factor β-induced protein (TGFBIp) are associated with TGFBI-linked corneal dystrophies, which manifests as protein deposits in the cornea. A total of 70 different disease-causing mutations have been reported so far including the common R124H substitution, which is associated with granular corneal dystrophy type 2 (GCD2). The disease mechanism of GCD2 is not known and the current treatments only offer temporary relief due to the reoccurrence of deposits. Experimental Design: The corneal protein profiles of the three genotypes (wild-type (WT), heterozygotes, and homozygotes) of a GCD2 mouse model are compared using label-free quantitative LC-MS/MS. Results: The mice do not display corneal protein deposits and the global protein expression between the three genotypes is highly similar. However, the expression of mutated TGFBIp is 41% of that of the WT protein. Conclusions and Clinical Relevance: It is proposed that the lowered expression level of mutant TGFBIp protein relative to WT protein is the direct cause of the missing development of corneal deposits in the mouse. The overall protein profiles of the corneas are not impacted by the reduced amount of TGFBIp. Altogether, this supports a partial reduction in mutated TGFBIp as a potential treatment strategy for GCD2.
AB - Purpose: Mutations in the transforming growth factor β-induced protein (TGFBIp) are associated with TGFBI-linked corneal dystrophies, which manifests as protein deposits in the cornea. A total of 70 different disease-causing mutations have been reported so far including the common R124H substitution, which is associated with granular corneal dystrophy type 2 (GCD2). The disease mechanism of GCD2 is not known and the current treatments only offer temporary relief due to the reoccurrence of deposits. Experimental Design: The corneal protein profiles of the three genotypes (wild-type (WT), heterozygotes, and homozygotes) of a GCD2 mouse model are compared using label-free quantitative LC-MS/MS. Results: The mice do not display corneal protein deposits and the global protein expression between the three genotypes is highly similar. However, the expression of mutated TGFBIp is 41% of that of the WT protein. Conclusions and Clinical Relevance: It is proposed that the lowered expression level of mutant TGFBIp protein relative to WT protein is the direct cause of the missing development of corneal deposits in the mouse. The overall protein profiles of the corneas are not impacted by the reduced amount of TGFBIp. Altogether, this supports a partial reduction in mutated TGFBIp as a potential treatment strategy for GCD2.
KW - 2DE immunoblotting
KW - cornea
KW - granular corneal dystrophy type 2
KW - label-free quantification
KW - transforming growth factor β-induced protein
UR - http://www.scopus.com/inward/record.url?scp=85087651970&partnerID=8YFLogxK
U2 - 10.1002/prca.201900072
DO - 10.1002/prca.201900072
M3 - Journal article
C2 - 32558206
AN - SCOPUS:85087651970
VL - 14
JO - Proteomics - Clinical Applications
JF - Proteomics - Clinical Applications
SN - 1862-8346
IS - 6
M1 - 1900072
ER -